These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 9865304)

  • 1. Pharmacoeconomic analysis of mycophenolate mofetil versus azathioprine in primary cadaveric renal transplantation.
    Baker GM; Martin JE; Jang R; Schroeder TJ; Armitstead JA; Myre S; First MR
    Transplant Proc; 1998 Dec; 30(8):4082-4. PubMed ID: 9865304
    [No Abstract]   [Full Text] [Related]  

  • 2. One-year, single-center cost analysis of mycophenolate mofetil versus azathioprine following cadaveric renal transplantation.
    Khosla UM; Martin JE; Baker GM; Schroeder TJ; First MR
    Transplant Proc; 1999; 31(1-2):274-5. PubMed ID: 10083105
    [No Abstract]   [Full Text] [Related]  

  • 3. The cost effectiveness of mycophenolate mofetil in the first year after primary cadaveric transplant. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sullivan SD; Garrison LP; Best JH
    J Am Soc Nephrol; 1997 Oct; 8(10):1592-8. PubMed ID: 9335389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate mofetil versus azathioprine in organ transplantation.
    Cravedi P; Perna A; Ruggenenti P; Remuzzi G
    Am J Transplant; 2009 Dec; 9(12):2856-7. PubMed ID: 19845579
    [No Abstract]   [Full Text] [Related]  

  • 5. [Economic contribution of mofetil mycofenolate as preventive immunosuppressive treatment after renal transplantation from cadaver].
    Louis-Touizer C; Nuijten MJ; Bayle F; Cantarovich D; Lang P; Lebranchu Y; Le Pogamp P; Touraine JL; Vialtel P; Monroe T; de Vries MJ
    Presse Med; 1996 Nov; 25(33):1577-82. PubMed ID: 8952671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postmarketing evaluation of mycophenolate mofetil-based triple therapy immunosuppression compared with a conventional azathioprine-based regimen reveals enhanced efficacy and early pharmacoeconomic benefit after renal transplantation.
    Wüthrich RP; Weinreich T; Schwarzkopf AK; Candinas D; Binswanger U
    Transplant Proc; 1998 Dec; 30(8):4096-7. PubMed ID: 9865310
    [No Abstract]   [Full Text] [Related]  

  • 7. Improved outcome of steroid withdrawal in mycophenolate mofetil-treated primary cadaveric renal transplant recipients.
    Kupin W; Venkat KK; Goggins M; Douzdjian V; Escobar F; Mozes M; Abouljoud M
    Transplant Proc; 1999; 31(1-2):1131-2. PubMed ID: 10083505
    [No Abstract]   [Full Text] [Related]  

  • 8. Mycophenolate mofetil eliminates the rationale for antilymphocyte induction therapy in nonhaploidentical living-donor kidney transplants.
    Shaffer D; Madras PN; Conway P; Davis C; Simpson MA; Monaco AP
    Transplant Proc; 1997; 29(1-2):342-3. PubMed ID: 9123031
    [No Abstract]   [Full Text] [Related]  

  • 9. Mofetil mycophenolate in renal transplantation.
    Pretagostini R; Rossi M; Berloco P; Colonnello M; Bruzzone P; Peritore D; Lonardo MT; Cortesini R
    Transplant Proc; 2001; 33(1-2):1082-3. PubMed ID: 11267200
    [No Abstract]   [Full Text] [Related]  

  • 10. Reduction in the incidence of early rejection in cadaveric renal allograft recipients treated with ATGAM induction and sequential mycophenolate mofetil.
    Florence LS; Howard DR; Chapman PH; Lieberman J; Perkinson DT; Marks WH
    Transplant Proc; 1997; 29(1-2):313-4. PubMed ID: 9123016
    [No Abstract]   [Full Text] [Related]  

  • 11. Mycophenolate mofetil--is it worth the cost? The in-favor opinion.
    Seikaly MG
    Pediatr Transplant; 1999 Feb; 3(1):79-82. PubMed ID: 10359036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil for the prevention of acute rejection of primary cadaveric kidney transplants: status of the MYC 1866 study at 1 year. The U.S. Mycophenolate Mofetil Study Group.
    Transplant Proc; 1997; 29(1-2):348-9. PubMed ID: 9123033
    [No Abstract]   [Full Text] [Related]  

  • 13. The treatment of chronic rejection with mycophenolate mofetil versus azathioprine in kidney transplantation.
    Jirasiritham S; Sumethkul V; Mavichak V; Chalermsanyakorn P
    Transplant Proc; 2000 Nov; 32(7):2040-2. PubMed ID: 11120057
    [No Abstract]   [Full Text] [Related]  

  • 14. Show me the money--immunosuppression in kidney transplantation.
    Burke GW; Ciancio G
    Lancet; 2004 Aug 7-13; 364(9433):481-3. PubMed ID: 15302174
    [No Abstract]   [Full Text] [Related]  

  • 15. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sollinger HW
    Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective randomised study of CSA monotherapy versus CSA plus mycophenolate mofetil in cadaveric renal transplant recipients.
    Sells RA; Bakran A; Brown MW; Grinyo J; Hammad A; Hyatt D; Owens G
    Transplant Proc; 1998 Dec; 30(8):4098. PubMed ID: 9865311
    [No Abstract]   [Full Text] [Related]  

  • 17. Decreased rejection episodes in African-American renal transplant recipients receiving mycophenolate mofetil/tacrolimus therapy.
    Weber M; Deng S; Arenas J; Aradhye S; Grossman R; Shaw L; Naji A; Barker C; Brayman KL
    Transplant Proc; 1997 Dec; 29(8):3669-70. PubMed ID: 9414883
    [No Abstract]   [Full Text] [Related]  

  • 18. The cost effectiveness of mycophenolate mofetil in the first year after living related renal transplantation.
    Süleymanlar G; Tuncer M; Sarikaya M; Ersoy F; Aktan S; Yakupoğlu G; Karpuzoğlu T
    Transplant Proc; 2001 Aug; 33(5):2780-1. PubMed ID: 11498158
    [No Abstract]   [Full Text] [Related]  

  • 19. The case of azathioprine versus mycophenolate. Do different drugs really cause different transplant outcomes?
    Craig JC; Webster AC; McDonald SP
    Transplantation; 2009 Mar; 87(6):803-4. PubMed ID: 19300180
    [No Abstract]   [Full Text] [Related]  

  • 20. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial.
    Remuzzi G; Lesti M; Gotti E; Ganeva M; Dimitrov BD; Ene-Iordache B; Gherardi G; Donati D; Salvadori M; Sandrini S; Valente U; Segoloni G; Mourad G; Federico S; Rigotti P; Sparacino V; Bosmans JL; Perico N; Ruggenenti P
    Lancet; 2004 Aug 7-13; 364(9433):503-12. PubMed ID: 15302193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.